ORION CORPORATION STOCK EXCHANGE RELEASE 4 MARCH 2019 at 12.00 EET
Orion Group Financial Statement documents 2018 and Corporate Governance Statement published
Orion Group's Financial Statement documents for 2018 have been published. The documents are available in Finnish and English on the Company's website at http://www.orion.fi/en.
The official Financial Statement documents, which include the Financial Statements, the Report by the Board of Directors and the Auditor's Report are available in Finnish at http://www.orion.fi/yhtiokokous2019.
Orion's Corporate Governance Statement for year 2018, adopted by the Board of Directors, is published as a separate report in Finnish and English on the Company's website at http://www.orion.fi/en.
Orion Corporation
| Olli Huotari SVP, Corporate Functions | Terhi Ormio VP, Communications |
Contact person:
Lilli Riikonen, Communications Manager, tel. +358 50 966 2319
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
